T1	intervention 26 59	doxorubicin plus cyclophosphamide
T2	control 65 96	docetaxel plus cyclophosphamide
T3	outcome-Measure 466 493	disease-free survival (DFS)
T6	total-participants 668 673	1,016
T7	intervention-participants 785 788	510
T8	control-participants 833 836	506
T9	outcome 1229 1237	DFS rate
T10	iv-bin-percent 1290 1293	86%
T11	cv-bin-percent 1296 1299	80%
T14	outcome 1374 1396	Overall survival rates
T15	iv-bin-percent 1416 1419	90%
T16	cv-bin-percent 1424 1427	87%
T19	outcome 1490 1541	myalgia, arthralgia, edema, and febrile neutropenia
T20	outcome 1571 1590	nausea and vomiting
T4	eligibility 530 629	stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor
T5	outcome 1641 1665	congestive heart failure
